Literature DB >> 16967572

Erythropoietin and hepatitis C therapy: useful adjuvant therapy but remember to treat the patient and not just a number.

Eric M Yoshida, Anne Dar Santos, Nilufar Partovi, Jo-Ann E Ford.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16967572      PMCID： PMC2659933          DOI： 10.1155/2006/793589

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN： 0835-7900            Impact factor:   3.522


× No keyword cloud information.
  13 in total

1.  IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000.

Authors: 
Journal:  Am J Kidney Dis       Date:  2001-01       Impact factor: 8.860

2.  Treating chronic hepatitis C with pegylated interferon alfa-2a (40 KD) and ribavirin in clinical practice.

Authors:  S S Lee; V G Bain; K Peltekian; M Krajden; E M Yoshida; M Deschenes; J Heathcote; R J Bailey; S Simonyi; M Sherman
Journal:  Aliment Pharmacol Ther       Date:  2006-02-01       Impact factor: 8.171

3.  Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage.

Authors:  L De Franceschi; G Fattovich; F Turrini; K Ayi; C Brugnara; F Manzato; F Noventa; A M Stanzial; P Solero; R Corrocher
Journal:  Hepatology       Date:  2000-04       Impact factor: 17.425

4.  Antibody-mediated pure red cell aplasia due to epoetin alfa during antiviral therapy of chronic hepatitis C.

Authors:  R Todd Stravitz; Harold Chung; Richard K Sterling; Velimir A Luketic; Arun J Sanyal; Angie S Price; Amy Purrington; Mitchell L Shiffman
Journal:  Am J Gastroenterol       Date:  2005-06       Impact factor: 10.864

Review 5.  Clinical recommendations for the use of recombinant human erythropoietin in patients with hepatitis C virus being treated with ribavirin.

Authors:  Morris Sherman; Lawrence Cohen; Mary Anne Cooper; Magdy Elkashab; Victor Feinman; David Fletcher; Nigel Girgrah; Jenny Heathcote; Mark Levstik; William B McNaull; David Wong; Florence Wong; Colina Yim
Journal:  Can J Gastroenterol       Date:  2006-07       Impact factor: 3.522

Review 6.  The clinical pharmacology of ribavirin.

Authors:  P Glue
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

7.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

8.  Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study.

Authors:  Nezam H Afdhal; Douglas T Dieterich; Paul J Pockros; Eugene R Schiff; Mitchell L Shiffman; Mark S Sulkowski; Teresa Wright; Zobair Younossi; Betty L Goon; K Linda Tang; Peter J Bowers
Journal:  Gastroenterology       Date:  2004-05       Impact factor: 22.682

9.  Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.

Authors:  Stephanos J Hadziyannis; Hoel Sette; Timothy R Morgan; Vijayan Balan; Moises Diago; Patrick Marcellin; Giuliano Ramadori; Henry Bodenheimer; David Bernstein; Mario Rizzetto; Stefan Zeuzem; Paul J Pockros; Amy Lin; Andrew M Ackrill
Journal:  Ann Intern Med       Date:  2004-03-02       Impact factor: 25.391

10.  Anemia in the treatment of hepatitis C virus infection.

Authors:  Mark S Sulkowski
Journal:  Clin Infect Dis       Date:  2003       Impact factor: 9.079
View more
  1 in total

Review 1.  Use of agents stimulating erythropoiesis in digestive diseases.

Authors:  Rosario Moreno López; Beatriz Sicilia Aladrén; Fernando Gomollón García
Journal:  World J Gastroenterol       Date:  2009-10-07       Impact factor: 5.742
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.